In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/j22-0077
Abstract: SOURCE CITATION Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.… read more here.
Keywords: previous treatment; treatment failures; eptinezumab safely; failures eptinezumab ... See more keywords